SG/CALL/VERTEX PHARMACEUTICALS/540/0.1/21.06.24 | End-of-day quote Boerse Frankfurt Warrants | ||
| - EUR | - |
|
| Current month | -96.43% | ||
| 3 months | -99.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
Static data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU7GDD |
| ISIN | DE000SU7GDD3 |
| Date issued | 25/01/2024 |
| Strike | 540 $ |
| Maturity | 21/06/2024 (3 Days) |
| Parity | 10 : 1 |
| Emission price | 0.7 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.7
USD
Average target price
463.4
USD
Spread / Average Target
-2.17%
- Stock Market
- Warrants
- Warrant